INGELHEIM, Germany–(BUSINESS WIRE)–
For media outside the UK, US and Canada
- Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®
- Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD
- Phase III data from MezzoTinA-asthma® trials evaluating the efficacy and safety of tiotropium† Respimat® in asthma patients symptomatic on moderate-dose maintenance inhaled corticosteroid (ICS) therapy
- Results of LUX-Lung 6 Phase III trial demonstrating superiority of afatinib‡ over standard chemotherapy in lung cancer patients with EGFR mutations1,2
Results from TIOSPIR™ (Tiotropium Safety and Performance in Respimat), one of the largest global chronic obstructive pulmonary disease (COPD) trials ever conducted, will be presented for the first time at the Annual Congress of the European Respiratory Society (ERS), in Barcelona, Spain, September 7-11, 2013.
The highly anticipated three year TIOSPIR™trial assessed the relative safety and efficacy of the two marketed SPIRIVA® formulations –SPIRIVA® Respimat® Soft Mist™ Inhaler 2.5 µg (once a day, 2 puffs§) versus SPIRIVA HandiHaler® 18 μg.** TIOSPIR™ included more than 17,000 COPD patients from 50 countries and, with broad inclusion criteria, featured a real-world study population that closely reflected the types of COPD patients physicians see every day. Boehringer Ingelheim is pleased to be sharing these results with the scientific community at the ERS Annual Congress, the largest respiratory meeting in the world.
Read the entire article at: